747-P: Improved Treatment Perceptions with IGlarLixi vs. Premix Insulin in Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) + Oral Antihyperglycemic Drugs (OADs): Patient-Reported Outcomes (PROs) of the SoliMix Trial

American Diabetes Association (ADA) 81st Annual Scientific Sessions

Back to home

Information is provided for scientific purposes only and may be outside the current labelling of the product. Sanofi does not recommend the use of any products in any manner inconsistent with that described in the full prescribing information. Please consult the prescribing information in your country of practice, as it can vary from country to country.

Availability of posters and/or abstracts on this site will coincide with ADA’s embargo policy.